Published in Clin Rheumatol on February 01, 2003
Overlapping juvenile idiopathic arthritis and systemic lupus erythematosus: a case report. Rheumatol Int (2010) 2.00
Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. Br J Ophthalmol (2004) 1.66
A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol (2011) 1.64
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther (2005) 1.58
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis (2004) 1.56
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther (2004) 1.38
Serious liver disease induced by infliximab. Clin Rheumatol (2006) 1.20
Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis (2004) 1.18
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther (2006) 1.17
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis (2004) 1.14
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int (2005) 1.06
Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med (2005) 0.97
Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis (2005) 0.96
Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis. Ann Rheum Dis (2004) 0.94
Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int (2004) 0.93
Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol (2008) 0.85
Adalimumab induced pulmonary sarcoid reaction. Respir Med Case Rep (2013) 0.83
Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr (2004) 0.82
Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother (2009) 0.82
Autoreactive preplasma cells break tolerance in the absence of regulation by dendritic cells and macrophages. J Immunol (2012) 0.80
Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol (2013) 0.79
Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol (2012) 0.78
A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent? Clin Rheumatol (2013) 0.78
Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci (2006) 0.78
The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag (2007) 0.76
Influenza A (H1N1) virus infection triggers severe pulmonary inflammation in lupus-prone mice following viral clearance. J Autoimmun (2015) 0.75
Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. Rheumatol Int (2006) 0.75
Episcleritis Related to Drug-Induced Lupus Erythematosus following Infliximab Therapy: A Case Report. Case Rep Med (2011) 0.75
Identification of Novel Single Chain Fragment Variable Antibodies Against TNF-α Using Phage Display Technology. Adv Pharm Bull (2015) 0.75
Production and Purification of a Novel Anti-TNF-α Single Chain Fragment Variable Antibody. Adv Pharm Bull (2015) 0.75
Male reproductive health and environmental xenoestrogens. Environ Health Perspect (1996) 4.11
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Crystal structure of a carbon monoxide dehydrogenase reveals a [Ni-4Fe-5S] cluster. Science (2001) 2.78
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis (2007) 2.75
SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum (1999) 2.70
Biology of aerobic carbon monoxide-oxidizing bacteria. Annu Rev Microbiol (1983) 2.52
Reisolation of the carbon monoxide utilizing hydrogen bacterium Pseudomonas carboxydovorans (Kistner) comb. nov. Arch Microbiol (1978) 2.39
Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology (Oxford) (2006) 2.15
Spinal tuberculosis in adults. A study of 103 cases in a developed country, 1980-1994. Medicine (Baltimore) (1999) 2.11
Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery. Acta Anaesthesiol Scand (2002) 2.02
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Two membrane-associated NiFeS-carbon monoxide dehydrogenases from the anaerobic carbon-monoxide-utilizing eubacterium Carboxydothermus hydrogenoformans. J Bacteriol (2001) 2.00
Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) (2013) 1.90
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum (2008) 1.90
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 1.88
Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.87
Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol (1996) 1.85
A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol (2003) 1.73
Carbon monoxide:methylene blue oxidoreductase from Pseudomonas carboxydovorans. J Bacteriol (1980) 1.68
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders. Arthritis Rheum (1999) 1.67
Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? Eur J Dermatol (2001) 1.64
Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology (1993) 1.64
Role of carboxydobacteria in consumption of atmospheric carbon monoxide by soil. Appl Environ Microbiol (1981) 1.62
Oxidation of carbon monoxide in cell extracts of Pseudomonas carboxydovorans. J Bacteriol (1979) 1.61
Crystal structure and mechanism of CO dehydrogenase, a molybdo iron-sulfur flavoprotein containing S-selanylcysteine. Proc Natl Acad Sci U S A (1999) 1.60
Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol (2001) 1.49
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum (2010) 1.47
Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol (1995) 1.46
Chemical and spectral properties of carbon monoxide: methylene blue oxidoreductase. The molybdenum-containing iron-sulfur flavoprotein from Pseudomonas carboxydovorans. J Biol Chem (1982) 1.45
Sequence analysis, characterization and CO-specific transcription of the cox gene cluster on the megaplasmid pHCG3 of Oligotropha carboxidovorans. Gene (1999) 1.43
Hippocrates on necrotising fasciitis. Lancet (1994) 1.43
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum (2009) 1.43
A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. Br J Rheumatol (1995) 1.43
Hypochromic vitiligo: delineation of a new entity. Br J Dermatol (2014) 1.42
Reliability of epidural pressure measurement in clinical practice: behavior of three modern sensors during simultaneous ipsilateral intraventricular or intraparenchymal pressure measurement. Neurosurgery (1998) 1.41
[Reasonable hospital use of mupirocin]. Ann Dermatol Venereol (2000) 1.40
[Treatment of arthroses in the elderly patient]. Presse Med (2000) 1.40
IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol (2000) 1.39
Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis (1993) 1.39
Molecular characterization of the gene cluster coxMSL encoding the molybdenum-containing carbon monoxide dehydrogenase of Oligotropha carboxidovorans. J Bacteriol (1995) 1.35
Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis (2004) 1.35
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus (2009) 1.28
Homology and distribution of CO dehydrogenase structural genes in carboxydotrophic bacteria. Arch Microbiol (1989) 1.27
Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) (2010) 1.25
Immunocytochemical localization of carbon monoxide oxidase in Pseudomonas carboxydovorans. The enzyme is attached to the inner aspect of the cytoplasmic membrane. J Biol Chem (1984) 1.25
Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol (1999) 1.25
Rheumatoid arthritis-like disease after alpha-interferon therapy. Ann Intern Med (1992) 1.24
Partition coefficient of a surfactant between aggregates and solution: application to the micelle-vesicle transition of egg phosphatidylcholine and octyl beta-D-glucopyranoside. Biophys J (1995) 1.22
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis (2010) 1.22
Selenium in biology: facts and medical perspectives. Biol Chem (2001) 1.21
Carbon monoxide dehydrogenase activity in Bradyrhizobium japonicum. Appl Environ Microbiol (2000) 1.21
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann Rheum Dis (2010) 1.19
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis (2012) 1.16
Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) (2008) 1.15
Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J Clin Immunol (2008) 1.13
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum (1994) 1.12
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum (2008) 1.11
Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population. J Dermatol Sci (2005) 1.11
Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet (2004) 1.10
Characterization of xanthine dehydrogenase from the anaerobic bacterium Veillonella atypica and identification of a molybdopterin-cytosine-dinucleotide-containing molybdenum cofactor. Eur J Biochem (1996) 1.10
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis (2012) 1.09
IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60-kD SSA/Ro protein. Clin Exp Immunol (1992) 1.07
Molybdopterin in carbon monoxide oxidase from carboxydotrophic bacteria. J Bacteriol (1984) 1.07
Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol (1998) 1.07
Hypocomplementemic urticarial vasculitis syndrome, Jaccoud's syndrome, valvulopathy: a new syndromic combination. J Rheumatol (1993) 1.06
Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
Studies by e.p.r. spectroscopy of carbon monoxide oxidases from Pseudomonas carboxydovorans and Pseudomonas carboxydohydrogena. Biochem J (1983) 1.05
Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev (2012) 1.05
Aspergillus spondylodiscitis: successful conservative treatment in 9 cases. J Rheumatol (1994) 1.04
The effect of intracellular molybdenum in Hydrogenophaga pseudoflava on the crystallographic structure of the seleno-molybdo-iron-sulfur flavoenzyme carbon monoxide dehydrogenase. J Mol Biol (2000) 1.04
A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford) (2006) 1.04
Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett (1997) 1.03
Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology (2001) 1.03
Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol (1992) 1.03
[Epidemiological aspects of osteoarticular tuberculosis in adults. Retrospective study of 206 cases diagnosed in the Paris area from 1980 to 1994]. Presse Med (1997) 1.02
Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol (1999) 1.02
Selenite binding to carbon monoxide oxidase from Pseudomonas carboxydovorans. Selenium binds covalently to the protein and activates specifically the CO----methylene blue reaction. J Biol Chem (1984) 1.01
Spontaneous spinal epidural hematoma with spinal cord compression complicating plasma cell myeloma. A case report. Spine (Phila Pa 1976) (1998) 1.01
Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol (1999) 1.01
Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol (1985) 1.00
The structural genes encoding CO dehydrogenase subunits (cox L, M and S) in Pseudomonas carboxydovorans OM5 reside on plasmid pHCG3 and are, with the exception of Streptomyces thermoautotrophicus, conserved in carboxydotrophic bacteria. Arch Microbiol (1992) 1.00
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) (2006) 1.00
First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost (1999) 1.00
Laurdan solvatochromism: solvent dielectric relaxation and intramolecular excited-state reaction. Biophys J (1997) 0.99
Systemic vasculitis and epithelioma. A report of three cases with a literature review. Rev Rhum Engl Ed (1997) 0.99
Familial lupus erythematosus. Clinical and immunologic features of 125 multiplex families. Medicine (Baltimore) (2001) 0.99
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum (2011) 0.98
Streptomyces thermoautotrophicus sp. nov., a Thermophilic CO- and H(2)-Oxidizing Obligate Chemolithoautotroph. Appl Environ Microbiol (1990) 0.98
Adult Still's disease: part I. Manifestations and complications in sixty-five cases in France. Rev Rhum Engl Ed (1995) 0.98
[Antiphospholipid antibodies, thrombosis and lupus disease. Value of the assay of anticardiolipin antibodies by the ELISA technic]. Rev Rhum Mal Osteoartic (1985) 0.98
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum (2009) 0.98